ClinicalTrials.gg
CompletedNCT02351739KEYNOTE143Updated Sep 10, 2019Results posted

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

A Phase 2 interventional study of pembrolizumab and ACP-196 in combination with pembrolizumab in Metastatic Urothelial Carcinoma, sponsored by Acerta Pharma BV. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing pembrolizumab in Carcinoma, Transitional Cell — 9 open to participants now, 13 under way, 3 of them phase 3. pembrolizumab · Carcinoma, Transitional Cell.

Enrollment
8th of 28
78 · median 31
Started
2015
with 2 others
Phase 2
19 of 28
6 open now
Registered
1st of 28
by date

Among the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, this one is the 8th largest by enrollment, is one of 3 that started in 2015, is one of 19 in phase 2, and was the 1st registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

9 of the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer

03

Conditions studied

  • Metastatic Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • or cytologically confirmed urothelial carcinoma of the bladder or mixed histology bladder cancer
  • bladder cancer with disease progression on or after platinum-based chemotherapy
  • Any primary site of urothelial carcinoma including upper tract, renal pelvis, bladder, and ureters
  • Prior therapy with ≥ 1 systemic chemotherapy regimens for urothelial carcinoma
  • Presence of radiographically (defined as the presence of ≥ 1 lesion that measures ≥ 10 mm [≥ 15 mm for lymph nodes]
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior (other than bladder cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years of which will not limit survival to \< 2 years.
  • Known central nervous system and/or carcinomatous meningitis
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Other
    Pembrolizumab

    Arm 1: pembrolizumab monotherapy

    Drug: pembrolizumab

  • Other
    ACP-196 in combination with pembrolizumab

    Arm 2: ACP-196 in combination with pembrolizumab

    Drug: ACP-196 in combination with pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Overall Response

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Every 12 weeks for up to 2 years.

07

Results

Posted Sep 10, 2019

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Pembrolizumab MonotherapyArm 2- Acalabrutinib+Pembrolizumab
Started3840
Enrolled3840
Received study medication3540
Discontinued study3840
Completed00
Not completed3840

Outcome measures

PrimaryNumber of Participants With Overall Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Every 12 weeks for up to 2 years.
Reported as:
Count of participants · Participants
Number of Participants With Overall Response
ParticipantsPembrolizumabACP-196 in Combination With Pembrolizumab
Number of Participants With Overall Response98

Adverse events

Collected over Reported Adverse Events (AEs) include events starting on or after Day 0 and on or before Day 730.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Pembrolizumab Monotherapy25/35 (71.4%)15/35 (42.9%)34/35 (97.1%)
Arm 2 - Acalabrutinib+Pembrolizumab31/40 (77.5%)23/40 (57.5%)39/40 (97.5%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventArm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib+Pembrolizumab
Acute Kidney DiseaseRenal and urinary disorders2/355/40
SepsisInfections and infestations1/353/40
NauseaGastrointestinal disorders2/350/40
Urinary Tract InfectionInfections and infestations2/352/40
PneumoniaInfections and infestations2/351/40
AscitesGastrointestinal disorders0/352/40
HaematuriaRenal and urinary disorders1/352/40
VomitingGastrointestinal disorders1/350/40
DiarrheaGastrointestinal disorders1/350/40
Impaired Gastric EmptyingGastrointestinal disorders1/350/40
Most frequent other events
Showing 10 of 103
Most frequent other events
EventArm 1 - Pembrolizumab MonotherapyArm 2 - Acalabrutinib+Pembrolizumab
FatigueGeneral disorders16/3534/40
DiarrheaGastrointestinal disorders7/3516/40
Decreased AppetiteMetabolism and nutrition disorders14/3516/40
Alanine Aminotransferase IncreasedInvestigations3/3514/40
AnaemiaBlood and lymphatic system disorders8/3513/40
VomitingGastrointestinal disorders10/3513/40
NauseaGastrointestinal disorders11/3510/40
ConstipationGastrointestinal disorders5/3512/40
DyspnoeaRespiratory, thoracic and mediastinal disorders5/3512/40
Aspartate Aminotransferase IncreasedInvestigations2/3511/40

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PembrolizumabACP-196 in Combination With PembrolizumabTotal
Mean65.8 ± 11.0866.4 ± 8.5366.1 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)PembrolizumabACP-196 in Combination With PembrolizumabTotal
Female282957
Male71118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PembrolizumabACP-196 in Combination With PembrolizumabTotal
Hispanic or Latino101
Not Hispanic or Latino344074
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PembrolizumabACP-196 in Combination With PembrolizumabTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American213
White323769
More than one race000
Unknown or Not Reported011
08

Study locations

7 sites
  • University of Chicago
    Chicago, Illinois, United States
  • University of Michigan
    Ann Arbor, Michigan, United States
  • Durham, North Carolina, United States
  • James Cancer Hospital
    Columbus, Ohio, United States
  • Oregon Health and Science University
    Portland, Oregon, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Feb 2018, 34 months.

Results were first posted in Sep 2019, 1 year 7 months after primary completion.

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2015
First posted
Jan 30, 2015
StartActual
Apr 2015
Primary completionActual
Feb 2018
CompletionActual
Apr 2018
Results first posted
Sep 10, 2019
Last update
Sep 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02351739
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jan 30, 2015
Start date
Apr 2015
Primary completion
Feb 2018
Completion
Apr 2018
Results posted
Sep 10, 2019
Last update
Sep 10, 2019

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Pembrolizumab

Start the discussion